Hydergine LC Uses

sponsored
How times a day do you take this medicine?

What is Hydergine LC?

Hydergine LC belongs to the group of medicines known as ergot alkaloids. It is used to treat some mood, behavior, or other problems that may be due to changes in the brain from Alzheimer's disease or multiple small strokes.

Hydergine LC is different from other ergot alkaloids such as ergotamine and methysergide. It is not useful for treating migraine headache. The exact way Hydergine LC acts on the body is not known.

Hydergine LC is available only with your doctor's prescription.

Hydergine LC indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Mental deterioration; acute cerebrovascular conditions; prevention of migraine & vascular headaches, peripheral vascular disorders; subjective symptoms associated w/ arterial HTN.

How should I use Hydergine LC?

Use Hydergine LC as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.

  • Do not eat, drink, or smoke while you take Hydergine LC.
  • Place Hydergine LC beneath your tongue and allow it to dissolve completely.
  • Do not swallow, crush, or chew Hydergine LC.
  • If you miss a dose of Hydergine LC, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you miss more than 1 dose, contact your doctor.

Ask your health care provider any questions you may have about how to use Hydergine LC.

Uses of Hydergine LC in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

This medication is used to treat mild problems with mood, memory, concentration, or behavior in the elderly. It is believed to increase blood flow to the brain. It is a combination of 3 ergot alkaloids.

How to use H.E.A.

Take this medication by mouth, usually 3 times daily or as directed by your doctor.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same times each day.

It may take several weeks before you see any improvement from the medication. Tell your doctor if your condition persists or worsens.

Hydergine LC description

sponsored

Hydergine LC is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Hydergine LC is the only vasodilator that has shown mild benefits in the treatment of vascular dementia.

Hydergine LC dosage

Usual Adult Dose for Dementia

1 mg orally 3 times a day

Comments:

-The decision to treat an individual with an ill-defined decline in mental capacity may result in missing underlying conditions that could be reversible and treatable; great care should be exercised to exclude delirium secondary to systemic disease, primary neurological disease, or primary disturbance of mood as possible conditions prior to treatment.

-Continued clinical evaluation is necessary during treatment as the patient's condition may evolve sufficiently to allow for a specific diagnosis and specific alternative treatment.

Use: Symptomatic relief of an idiopathic decline in mental capacity effecting self-care, mood, motivation, cognitive and interpersonal skills.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

-Take orally 3 times a day

Storage requirements: Protect from light

General:

-As treatment with this drug means target symptoms are of unknown etiology, careful diagnosis should be attempted prior to prescribing.

-Once therapy begins, alleviation of symptoms may not be observed for 3 to 4 weeks.

-Modest efficacy was shown on the SCAG (Sandoz Clinical Assessment-Geriatric) scale including improvements to mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome (ness), and overall impression of clinical status at 12-weeks.

Monitoring:

-Monitor for reversible and treatable conditions

-Continually assess and rate improvements to ensure any initial benefit persists with time.

Patient advice:

-Transient nausea and gastric disturbances may occur.

-This drug does not possess the vasoconstrictor properties of natural ergot alkaloids.

Hydergine LC interactions

See also:
What other drugs will affect Hydergine LC?

sponsored

Antihepaciviral Combination Products: May increase the serum concentration of Ergot Derivatives. Avoid combination

Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives. Consider therapy modification

Chloroprocaine: May enhance the hypertensive effect of Ergot Derivatives. Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination

CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination. Some combinations are specifically contraindicated by manufacturers; others may have recommended dose adjustments. If combined, monitor for increased substrate effects. Consider therapy modification

Duvelisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Fosnetupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination

Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination

Itraconazole: May increase the serum concentration of Hydergine LC. Avoid combination

Ketoconazole (Systemic): May increase the serum concentration of Hydergine LC. Avoid combination

Larotrectinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Letermovir: May increase the serum concentration of Ergot Derivatives. Avoid combination

Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. Avoid combination

Macrolide Antibiotics: May increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. Exceptions: Azithromycin (Systemic); Fidaxomicin; Spiramycin. Avoid combination

MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. Consider therapy modification

Nefazodone: Ergot Derivatives may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Ergot Derivatives. Avoid combination

Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives. Avoid combination

Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Posaconazole: May increase the serum concentration of Hydergine LC. Avoid combination

Protease Inhibitors: May increase the serum concentration of Ergot Derivatives. Avoid combination

Reboxetine: May enhance the hypertensive effect of Ergot Derivatives. Monitor therapy

Roxithromycin: May increase the serum concentration of Ergot Derivatives. Avoid combination

Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: Nefazodone. Monitor therapy

Serotonin 5-HT1D Receptor Agonists (Triptans): Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists (Triptans). Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the vasoconstricting effect of Ergot Derivatives. Avoid combination

Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Consider therapy modification

Voriconazole: May increase the serum concentration of Hydergine LC. Avoid combination

Hydergine LC side effects

See also:
What are the possible side effects of Hydergine LC?

sponsored

Applies to Hydergine LC: capsule liquid filled, solution, tablet

In addition to its needed effects, some unwanted effects may be caused by Hydergine LC (the active ingredient contained in Hydergine LC LC). In the event that any of these side effects do occur, they may require medical attention.

Severity: Moderate

If any of the following side effects occur while taking Hydergine LC, check with your doctor or nurse as soon as possible:

Less common or rare:

  • Dizziness or lightheadedness when getting up from a lying or sitting position
  • drowsiness
  • skin rash
  • slow pulse
Signs and symptoms of overdose
  • Blurred vision
  • dizziness
  • fainting
  • flushing
  • headache
  • loss of appetite
  • nausea or vomiting
  • stomach cramps
  • stuffy nose

Minor Side Effects

Some of the side effects that can occur with Hydergine LC may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common or rare:

  • Soreness under tongue (with sublingual use)

Hydergine LC contraindications

See also:
What is the most important information I should know about Hydergine LC?

Hydergine LC® (Hydergine LC) preparations are contraindicated in individuals who have previously shown hypersensitivity to the drug. Hydergine LC® (Hydergine LC) preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.

Active ingredient matches for Hydergine LC:

Ergoloid Mesylates

Ergoloid mesylate


Unit description / dosage (Manufacturer)Price, USD
Capsule; Oral; Ergoloid Mesylates 1 mg

List of Hydergine LC substitutes (brand and generic names):

Tablet; Sublingual; Ergoloid Mesylates 0.5 mg
Tablet; Sublingual; Ergoloid Mesylates 1 mg
Tablet; Oral; Ergoloid Mesylates 1 mg
Tablet; Oral; Ergoloid Mesylates 0.5 mg
100 tablet in 1 bottle
1000 tablet in 1 bottle
250 tablet in 1 bottle
Solution; Oral; Ergoloid Mesylates 5 mg / 5 ml (Novartis India Ltd)
Tablet; Oral; Ergoloid Mesylates 0.5 mg (Novartis India Ltd)
Tablet; Oral; Ergoloid Mesylates 1 mg (Novartis India Ltd)
Tablet; Oral; Ergoloid Mesylates 4.5 mg (Novartis India Ltd)
HYDERGINE Capsule/ Tablet / 1mg / 1x10 units (Novartis India Ltd)$ 3.23
HYDERGINE Injection / 0.3mg per ml / 6x1ml Inj units (Novartis India Ltd)$ 2.77
Hydergine 1 mg x 100's (Novartis India Ltd)$ 79.32
Hydergine 1mg TAB / 90 (Novartis India Ltd)$ 7.57
Hydergine 0.3mg/ml INJ / 6*1ml (Novartis India Ltd)$ 2.77
1 mg x 90's (Novartis India Ltd)$ 7.57
0.3 mg x 1 mL x 6x1ml (Novartis India Ltd)$ 2.77
Hydergine 1.5 mg x 100's (Novartis India Ltd)
Hydergine 1.5 mg x 500's (Novartis India Ltd)
Hydergine 0.3 mg/1 mL (Novartis India Ltd)
Hydergine / amp 300 mcg/1 mL x 1 mL x 10's (Novartis India Ltd)$ 40.55
Hydergine / FP 1 mg x 500's (Novartis India Ltd)
Hydergine 300 mg/1 mL x 5's (Novartis India Ltd)
Hydergine FAS 4.5 mg x 30's (Novartis India Ltd)
Hydergine 1 mg Tablet (Novartis India Ltd)$ 0.37
Hydergine 0.3 mg Injection (Novartis India Ltd)$ 0.46
HYDERGINE tab 1 mg x 10's (Novartis India Ltd)$ 0.76
HYDERGINE inj 0.3 mg x 1 mL x 1ml (Novartis India Ltd)$ 0.46

References

  1. PubChem. "Ergoloid mesylate". https://pubchem.ncbi.nlm.nih.gov/sub... (accessed September 17, 2018).
  2. DrugBank. "Ergoloid mesylate - DrugBank". http://www.drugbank.ca/drugs/DB01049 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Hydergine LC are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Hydergine LC. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


1 consumer reported age

Users%
30-451
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 22 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved